Cell Therapy News

Socioeconomic status had no impact on complete remission rates or overall survival among younger patients who received chimeric antigen receptor T-cell therapy for B-cell acute lymphoblastic leukemia, study results showed.

The addition of a cell-based immune primer to sunitinib exhibited activity among patients with metastatic renal cell carcinoma, according to randomized phase 2 study results.

Dual administration of CD19- and CD22-directed chimeric antigen receptor T cells conferred a 99% complete remission rate in younger patients with relapsed or high-risk B-cell acute lymphoblastic leukemia, phase 2 study results showed.

Guidelines on revaccination after cell therapy are clear for some patients but lack evidence-based consensus for others, according to an expert in infectious disease who spoke at NCCN 2022 Annual Congress: Hematologic Malignancies.

The FDA granted fast track designation to MT-101, an investigational chimeric antigen receptor monocyte, for the treatment of relapsed or refractory peripheral T-cell lymphoma.

Three-quarters of patients with advanced B-cell malignancies who received an investigational chimeric antigen receptor T-cell therapy achieved complete response, according to the agent’s manufacturer.

Carl H. June, MD, will receive the inaugural Maria I. New International Prize for Biomedical Research.

Four individuals have been elected to American Society of Hematology’s executive committee.

Novel B-cell maturation antigen-directed immunotherapies are ready to take their place as the new standard for treatment of advanced multiple myeloma, according to a panel at NCCN 2022 Annual Congress: Hematologic Malignancies.

Emerging evidence has shown chimeric antigen receptor T-cell therapies are highly effective regardless of a patient’s race or ethnicity.